Zeenews Bureau In what may be seen as a positive development, it has emerged that the anti-estrogen drug Aromasin reduces the risk of breast cancer recurrence by about one-third in postmenopausal women previously treated with tamoxifen. According to researchers, `Aromasin`, which has been approved by the FDA, obstructs the production of estrogen that is made outside of the ovaries.
Two other drugs, tamoxifen and raloxifene have also been approved by the FDA for cancer prevention though they have side effects like blood clots, strokes, leg cramps and joint pain.
Pakistan violates ceasefire again, opens fire at RS Pura sector in J&K
Modi to lead BJP Parliamentary Party in both houses of Parliament
BJP will continue animosity with Moradabad SSP for years: Laxmikant Bajpai
UPSC aspirants protest outside Rajnath Singh`s residence